These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 10357418)

  • 1. p53 alteration in regional lymph node metastases from prostate carcinoma: a marker for progression?
    Cheng L; Leibovich BC; Bergstralh EJ; Scherer BG; Pacelli A; Ramnani DM; Zincke H; Bostwick DG
    Cancer; 1999 Jun; 85(11):2455-9. PubMed ID: 10357418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen receptor expression in prostate cancer lymph node metastases is predictive of outcome after surgery.
    Sweat SD; Pacelli A; Bergstralh EJ; Slezak JM; Cheng L; Bostwick DG
    J Urol; 1999 Apr; 161(4):1233-7. PubMed ID: 10081876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of p53 and c-myc overrepresentation in stage T(2-3)N(1-3)M(0) prostate cancer are potential markers for cancer progression.
    Qian J; Hirasawa K; Bostwick DG; Bergstralh EJ; Slezak JM; Anderl KL; Borell TJ; Lieber MM; Jenkins RB
    Mod Pathol; 2002 Jan; 15(1):35-44. PubMed ID: 11796839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell proliferation in prostate cancer patients with lymph node metastasis: a marker for progression.
    Cheng L; Pisansky TM; Sebo TJ; Leibovich BC; Ramnani DM; Weaver AL; Scherer BG; Blute ML; Zincke H; Bostwick DG
    Clin Cancer Res; 1999 Oct; 5(10):2820-3. PubMed ID: 10537347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dedifferentiation in the metastatic progression of prostate carcinoma.
    Cheng L; Slezak J; Bergstralh EJ; Cheville JC; Sweat S; Zincke H; Bostwick DG
    Cancer; 1999 Aug; 86(4):657-63. PubMed ID: 10440694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extranodal extension in lymph node-positive prostate cancer.
    Cheng L; Pisansky TM; Ramnani DM; Leibovich BC; Cheville JC; Slezak J; Bergstralh EJ; Zincke H; Bostwick DG
    Mod Pathol; 2000 Feb; 13(2):113-8. PubMed ID: 10697266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53 protein overexpression is associated with increased cell proliferation in patients with locally recurrent prostate carcinoma after radiation therapy.
    Cheng L; Sebo TJ; Cheville JC; Pisansky TM; Slezak J; Bergstralh EJ; Pacelli A; Neumann RM; Zincke H; Bostwick DG
    Cancer; 1999 Mar; 85(6):1293-9. PubMed ID: 10189134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of p53 nuclear accumulation in localized prostate cancer treated with radical prostatectomy.
    Quinn DI; Henshall SM; Head DR; Golovsky D; Wilson JD; Brenner PC; Turner JJ; Delprado W; Finlayson JF; Stricker PD; Grygiel JJ; Sutherland RL
    Cancer Res; 2000 Mar; 60(6):1585-94. PubMed ID: 10749127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disease progression and survival in patients with prostate carcinoma and positive lymph nodes after radical retropubic prostatectomy.
    Kroepfl D; Loewen H; Roggenbuck U; Musch M; Klevecka V
    BJU Int; 2006 May; 97(5):985-91. PubMed ID: 16643480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. P53 expression in squamous cell carcinomas of the supraglottic larynx and its lymph node metastases: new results for an old question.
    Cabanillas R; Rodrigo JP; Astudillo A; Domínguez F; Suárez C; Chiara MD
    Cancer; 2007 May; 109(9):1791-8. PubMed ID: 17380529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of p53 mutations with metastatic prostate cancer.
    Eastham JA; Stapleton AM; Gousse AE; Timme TL; Yang G; Slawin KM; Wheeler TM; Scardino PT; Thompson TC
    Clin Cancer Res; 1995 Oct; 1(10):1111-8. PubMed ID: 9815901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era.
    Boorjian SA; Thompson RH; Siddiqui S; Bagniewski S; Bergstralh EJ; Karnes RJ; Frank I; Blute ML
    J Urol; 2007 Sep; 178(3 Pt 1):864-70; discussion 870-1. PubMed ID: 17631342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p53 as a new prognostic factor for lymph node metastasis in penile carcinoma: analysis of 82 patients treated with amputation and bilateral lymphadenectomy.
    Lopes A; Bezerra AL; Pinto CA; Serrano SV; de MellO CA; Villa LL
    J Urol; 2002 Jul; 168(1):81-6. PubMed ID: 12050497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Caveolin-1 expression is a predictor of recurrence-free survival in pT2N0 prostate carcinoma diagnosed in Japanese patients.
    Satoh T; Yang G; Egawa S; Addai J; Frolov A; Kuwao S; Timme TL; Baba S; Thompson TC
    Cancer; 2003 Mar; 97(5):1225-33. PubMed ID: 12599229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of proliferating cell nuclear antigen immunostaining in lymph node metastases and primary prostate adenocarcinoma after neoadjuvant androgen deprivation therapy.
    Minardi D; Galosi AB; Giannulis I; Montironi R; Polito M; Muzzonigro G
    Scand J Urol Nephrol; 2004; 38(1):19-25. PubMed ID: 15204422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome prediction with p53 immunostaining after radical prostatectomy in patients with locally advanced prostate cancer.
    Leibovich BC; Cheng L; Weaver AL; Myers RP; Bostwick DG
    J Urol; 2000 Jun; 163(6):1756-60. PubMed ID: 10799176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure?
    Bader P; Burkhard FC; Markwalder R; Studer UE
    J Urol; 2003 Mar; 169(3):849-54. PubMed ID: 12576797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of neuroendocrine expression in lymph node-positive prostate cancer.
    Quek ML; Daneshmand S; Rodrigo S; Cai J; Dorff TB; Groshen S; Skinner DG; Lieskovsky G; Pinski J
    Urology; 2006 Jun; 67(6):1247-52. PubMed ID: 16697447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era.
    DiMarco DS; Zincke H; Sebo TJ; Slezak J; Bergstralh EJ; Blute ML
    J Urol; 2005 Apr; 173(4):1121-5. PubMed ID: 15758719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of pelvic lymph node metastasis by the ratio of cathepsin B to stefin A in patients with prostate carcinoma.
    Sinha AA; Quast BJ; Wilson MJ; Fernandes ET; Reddy PK; Ewing SL; Gleason DF
    Cancer; 2002 Jun; 94(12):3141-9. PubMed ID: 12115346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.